Added Value of a Neuroendocrine Test Battery in the Response to Repetitive

Status Recruiting

Clinical Trial Summary

The primary objective of the study is to determine the predictive value of the neuroendocrine tests TRH-∆∆TSH (thyreoliberin - thyreostimulin) and DST (dexamethasone suppression test) in the subsequent response to rTMS-TBS (repetitive transcranial magnetic stimulation-theta burst stimulation) treatment, defined as at least a 50% decrease in depression score after 20 sessions of rTMS-TBS.

Clinical Trial Description

Conduct of research : This is a monocentric, non-randomized, open-label pilot study involving 50 male and female patients aged 18 to 65, hospitalized for major depression and presenting with an indication for treatment with repeated theta-burst transcranial magnetic stimulation (rTMS-TBS), i.e. a situation of therapeutic failure following 2 well-conducted antidepressant treatments. At the end of the 20 rTMS-TBS sessions (one session per day, except weekends), the clinical response will be assessed by an investigator "blind" to the endocrine results. This response will be analyzed according to the status of neuroendocrine tests at inclusion (TRH-∆∆TSH and DST) and at the end of the study (for those who had one or more abnormal tests at inclusion and in whom the same tests were repeated at the end of the rTMS-TBS sessions). During the inclusion visit, the patient and investigator sign the consent form, after double-checking the inclusion and non-inclusion criteria. Immediately after the tenth rTMS session, an assessment of depression using the HAMD (17-item Hamilton Depression Scale) scale will be carried out by an independent psychiatrist, blind to the results of the neuroendocrine tests. This psychiatrist, who has already administered the HAMD at V0, will repeat the assessments at V1 and V2. Immediately after the twentieth rTMS session, an assessment of depression using the HAMD scale will be carried out by an independent psychiatrist. This assessment will determine responder/non-responder status to rTMS-TBS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05964192
Study type	Interventional
Source	Centre Hospitalier Rouffach
Contact	MIHAELA TOMSA
Phone	+33 389787018
Email	m.tomsa@ch-rouffach.fr
Status	Recruiting
Phase	N/A
Start date	April 1, 2024
Completion date	June 30, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03062150` - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression	N/A
Completed	`NCT04352101` - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits	Phase 4
Completed	`NCT02855918` - Blood Biomarkers in Suicidal Behaviour	N/A
Recruiting	`NCT03039387` - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	N/A
Recruiting	`NCT02213016` - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients	Phase 4
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Completed	`NCT01683539` - Understanding How Cognitive Remediation Works	N/A
Recruiting	`NCT02237937` - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Phase 4
Completed	`NCT01201148` - Open Pilot Trial of TES for Depression	Phase 2
Completed	`NCT00953108` - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Phase 3
Terminated	`NCT00695552` - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients	N/A
Completed	`NCT00806143` - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression	Phase 4
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Completed	`NCT00532480` - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine	Phase 4
Completed	`NCT00482482` - Yoga in Unipolar and Bipolar Disorders	N/A
Completed	`NCT00466323` - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.	N/A
Completed	`NCT00616759` - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol	N/A
Recruiting	`NCT00209807` - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder	Phase 4
Completed	`NCT00149110` - Chronos: the Use of Chronobiological Treatment in Depression	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment — Endo-rTMS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms